Benzodiazepine use and risk of recurrence in bipolar disorder: A STEP-BD report

Journal of Clinical Psychiatry

Volumn 71, Issue 2, 2010, Pages 194-200

  Perlis, Roy H ^a   Ostacher, Michael J ^a   Miklowitz, David J ^b   Smoller, Jordan W ^a   Dennehy, Ellen B ^c   Cowperthwait, Colleen ^a   Nierenberg, Andrew A ^a   Thase, Michael E ^d   Sachs, Gary S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PURDUE UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE;

ADULT; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION; SCORING SYSTEM; SURVIVAL; TREATMENT OUTCOME;

ADULT; BENZODIAZEPINES; BIPOLAR DISORDER; COHORT STUDIES; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; RISK; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77649130256     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05019yel     Document Type: Article

References (38)

1. Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry. 2004;65(2):151-155.
2. Ghaemi SN, Hsu DJ, Thase ME, et al. Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. Psychiatr Serv. 2006;57(5):660-665.
3. Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004;161(12):2222-2229.
4. Plante DT, Winkelman JW. Sleep disturbance in bipolar disorder: therapeutic implications. Am J Psychiatry. 2008;165(7):830-843.
5. Simon NM, Otto MW, Weiss RD, et al. STEP-BD Investigators. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004;24(5): 512-520.
6. Hirschfeld RA, Bowden CL, Gitlin MJ, et al. Practice Guideline for the Treatment of Patients With Bipolar Disorder (revision). Am J Psychiatry. 2002;159(suppl 4):1-50.
7. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Panic Disorder. Am J Psychiatry. 1998; 155(suppl 5):1-34.
8. Chouinard G, Young SN, Annable L. Antimanic effect of clonazepam. Biol Psychiatry. 1983;18(4):451-466.
9. Bradwejn J, Shriqui C, Koszycki D, et al. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol. 1990;10(6):403-408.
10. Edwards R, Stephenson U, Flewett T. Clonazepam in acute mania: a double blind trial. Aust N Z J Psychiatry. 1991;25(2):238-242.
11. Bottaï T, Hüe B, Hillaire-Buys D, et al. Clonazepam in acute mania: time-blind evaluation of clinical response and concentrations in plasma. J Affect Disord. 1995;36(1-2):21-27.
12. Sachs GS, Rosenbaum JF, Jones L. Adjunctive clonazepam for maintenance treatment of bipolar affective disorder. J Clin Psychopharmacol. 1990;10(1):42-47.
13. Hwang G, Kim HR, Park SH, et al. Do benzodiazepines extend the duration of follow-up treatment in patients with bipolar disorder? Hum Psychopharmacol. 2006;21(5):319-325.
14. Winkler D, Willeit M, Wolf R, et al. Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder. Eur Neuropsychopharmacol. 2003;13(2):129-134.
15. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225-233.
16. Gualtieri CT, Morgan DW. The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials. J Clin Psychiatry. 2008;69(7): 1122-1130.
17. Mur M, Portella MJ, Martínez-Arán A, et al. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. J Clin Psychiatry. 2008;69(5):712-719.
18. Simonsen C, Sundet K, Vaskinn A, et al. Neurocognitive profiles in bipolar I and bipolar II disorder: differences in pattern and magnitude of dysfunction. Bipolar Disord. 2008;10(2):245-255.
19. Dickerson F, Boronow JJ, Stallings C, et al. Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status. Psychiatry Res. 2004;129(1):45-53.
20. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry. 2003;53(11):1028-1042.
21. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163(2):217-224.
22. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57.
23. Sachs GS, Guille C, McMurrich SL. A clinical monitoring form for mood disorders. Bipolar Disord. 2002;4(5):323-327.
24. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
25. Dennehy EB, Bauer MS, Perlis RH, et al. Concordance with treatment guidelines for bipolar disorder: data from the Systematic Treatment Enhancement Program for Bipolar Disorder. Psychopharmacol Bull. 2007;40(3):72-84.
26. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261-269.
27. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537.
28. Keller MB, Lavori PW, Coryell W, et al. Bipolar I: a five-year prospective follow-up. J Nerv Ment Dis. 1993;181(4):238-245.
29. Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160(12):2099-2107.
30. Mangano DT, Miao Y, Vuylsteke A, et al. Ischemia Research and Education Foundation. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007;297(5):471-479.
31. Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006;296(17):2105-2111.
32. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008;359(13):1330-1342.
33. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335-2341.
34. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98(3):253-259.
35. Otto MW, Simon NM, Wisniewski SR, et al. STEP-BD Investigators. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006;189(1): 20-25.
36. Gruber SA, Rosso IM, Yurgelun-Todd D. Neuropsychological performance predicts clinical recovery in bipolar patients. J Affect Disord. 2008;105(1-3):253-260.
37. Menzies L, Ooi C, Kamath S, et al. Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry. 2007;64(2):156-167.
38. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(suppl 5):7-12.